Mercaptopurine has been used in continuing treatment of childhood acute lymphoblastic leukaemia since the mid 1950s. Recent advances in the understanding of thiopurine pharmacology indicated that thioguanine (TG) might be more effective than mercaptopurine (MP). The US and UK cooperative groups began randomised thiopurine trials and agreed prospectively to a meta-analysis. All randomised trials of TG versus MP were sought, and data on individual patients were analysed by standard methods. Combining three trials (from US, UK and Germany), the overall event-free survival (EFS) was not significantly improved with TG (odds ratio (OR) ¼ 0.89; 95% confidence interval 0.78-1.03). Apparent differences in results between trials may be partly explained by the different types of patients studied. The larger treatment effect reported in males in the US trial was confirmed in the other trials. There was heterogeneity between sex/age subgroups (P ¼ 0.001), with significant EFS benefit of TG only observed for males aged o10 years old (OR ¼ 0.70; 0.58-0.84), although this did not result in a significant difference in overall survival (OR ¼ 0.83; 0.62-1.10). Additional toxicity occurs with TG. Mercaptopurine remains the standard thiopurine of choice, but further study of TG may be warranted to determine whether it could benefit particular subgroups. Leukemia (2011) 25, 953-959; 
Introduction
It has long been recognised that thiopurines are critical components in the treatment for acute lymphoblastic leukaemia (ALL). In childhood ALL, mercaptopurine (MP) has usually been used in daily long-term maintenance therapy, with thioguanine (TG) limited to intensification blocks. Research since the 1980s on the metabolism of the two drugs has suggested theoretical reasons on why TG might be more effective. Therefore, in the 1990s, trials were initiated to compare the clinical effectiveness of the two thiopurines.
A worldwide collaboration of trialists had previously been formed, whose aim was to perform meta-analyses of randomised trials using individual patient data on the most important current questions. At the start of the US Childhood Cancer Group (CCG) and the UK Medical Research Council (MRC) randomised trials comparing TG and MP, it was agreed prospectively that when complete, the trials would be combined in a meta-analysis. Searches of MEDLINE, EMBASE and clinical trial databases, meeting abstracts, review articles and reference lists found an additional trial addressing the same thiopurine question and this study was included to perform a comprehensive meta-analysis.
The co-operative study group for childhood acute lymphoblastic leukaemia (COALL)-05-92 trial reported its results first 1 and found no evidence of benefit for TG over MP, with similar event-free survival (EFS) in the two treatment arms. Furthermore, the use of TG was complicated by prolonged myelosuppression with marked thrombocytopenia. However, a small, but clinically worthwhile, benefit could not be ruled out as less than 500 patients were randomised and no major side effects were seen. The report of MRC ALL97 2 concluded that TG caused excess toxicity without an overall benefit. A reduction in the risk of central nervous system (CNS) relapse was offset by an increased risk of death in remission and there was evidence of greatly increased hepatic toxicity with TG. In contrast, the CCG-1952 trial reported as an abstract in 2002 3 that EFS was significantly better with TG by 8% at 5 years. However, as in the UK trial, TG-induced veno-occlusive disease (VOD) of the liver forced many patients to switch from TG to MP. During the course of this trial, the dose of TG was reduced from 60 to 50 mg/m 2 , and the greatest difference in EFS between TG and MP was seen for boys who began at a dosage of 60 mg/m 2 . The recent publication of CCG-1952 4 confirmed a 5% better EFS at 7 years, because of decreased bone marrow and isolated CNS relapses, but no increase in overall survival (OS) was observed.
Materials and methods
Data were received on each patient randomised between MP and TG in the COALL-05-92, CCG-1952 and MRC ALL97 trials. They were checked for internal consistency, balance between treatment groups by initial features, randomisation dates and length of follow-up and consistency with publications. Queries were sorted out by correspondence with the trialists, who were also sent summary tabulations to check that the data had been correctly interpreted.
Analyses were of time from randomisation to event within trial, with the observed minus expected (O-E) number of events and its variance, obtained by the log-rank method, added over the three trials, used to calculate an overall odds ratio (OR) and its 95% confidence interval (CI). Descriptive curves were drawn using these statistics. 5 Outcomes analysed were CNS relapse, non-CNS relapse, secondary tumour, death without remission and death in remission. For each of these outcomes, only the first event was counted for each patient, censoring at other event types. Event-free survival, including all these event types, was the primary outcome measure, and OS was also analysed. Heterogeneity between trials was tested using w 2 -statistics and the I 2 -measure of consistency. 6 Subgroup analyses were pre-specified by gender, age group (o10, X10 years), white blood count (WBC) (o10, 10-19, 20-49, 50-99, X100) and immunophenotype (B lineage, T lineage). In the reported analyses, the two highest WBC groups were combined because the numbers were small. Table 1 shows the recruitment period, main eligibility criteria and treatment comparison for the three trials. The COALL and MRC trials included all ALL risk groups, whereas CCG-1952 was only for National Cancer Institute standard-risk children (age o10 years and WBCo50 Â 10 9 /l).
Results
The COALL-05-92 treatment regimen consisted of a 7-day pre-phase with daunorubicin and intrathecal (IT) methotrexate (MTX), induction with vincristine, daunorubicin and methylprednisolone, intensification, CNS prophylaxis, reinduction and maintenance till 2 years. Children aged X10 years, with WBCX25 Â 10 9 /l or T or pre-pre-B-ALL were considered high risk and had two additional treatment blocks in intensification and had longer reinduction. CNS prophylaxis consisted of IT MTX (18 doses given overall, with 4 given during the phase defined as CNS prophylaxis and 6 given during maintenance). Cranial irradiation (12 Gy) was given to high risk children with WBCX25 Â 10 9 /l or T-ALL (from April 1994 this was changed to WBCX50 Â 10 9 /l or T-ALL), and 18 Gy to those with CNS disease. Re-induction and maintenance IT doses were omitted in patients who received cranial irradiation so that they received only nine doses of IT MTX overall.
The CCG-1952 treatment consisted of induction with IT cytarabine, vincristine, asparaginase, prednisone and IT MTX, consolidation, interim maintenance, two intensification blocks and maintenance till 2.25 years for girls and 3.25 years for boys. Only rapid early responders (p25% blasts at day 15) were randomised for thiopurine. Patients were additionally randomised in a factorial design, between IT MTX and triple IT therapy (MTX, cytarabine, hydrocortisone sodium succinate), with all patients receiving two doses of IT MTX in induction plus 17 doses (girls) or 21 doses (boys) of IT MTX or triple IT overall according to the randomised allocation. Craniospinal irradiation (24 Gy cranial, 0.6 Gy spinal) was administered to those with CNS disease at diagnosis during the consolidation phase.
MRC ALL97 included a randomisation between the steroids prednisolone and dexamethasone. Treatment consisted of induction with vincristine, allocated steroid, asparaginase, IT MTX, two short intensification blocks with CNS prophylaxis in between, interim maintenance, further intensification and maintenance till 2 years. CNS prophylaxis consisted of a total of 16 doses of IT MTX for those with WBCo50 Â 10 9 /l, or three doses of high-dose MTX (6 or 8 g/m 2 ) plus 16 doses of IT MTX or 24 Gy cranial irradiation plus nine doses of IT MTX for WBC X50 Â 10 9 /l (randomised). In November 1999, there was a major revision. From this time, the treatment for standard-risk children with rapid early response was similar to CCG-1952, apart from the randomisation of the steroid. High-risk children received daunorubicin additionally in induction and more intensive consolidation. All children classified as slow early responders during induction (425 % blasts at day 15 if standard Table 1 Trial descriptions Adjusted to maintain WBC 2-3 Â 10 9 /l Adjusted to maintain neutrophils 1-2 Â 10 9 /l and platelets X100 Â 10 9 /l Adjusted to maintain neutrophils X1.0 Â 10 9 /l and platelets X100 Â 10 9 /l, but as low as possible (ALL 97) or neutrophils between 0.75 and 1.5 Â 10 9 /l and platelets 475 Â 10 9 /l (ALL 97/99 risk, or at day 8 if high risk) were switched to a more intensive regimen with augmented consolidation and more vincristine, oral MTX and polyethylene glycol (PEG) asparaginase during the interim maintenance periods. Girls were treated for 2 years and boys for 3 years. Girls received 19 or 22 doses of IT MTX overall, and boys received 23 or 26 doses, with those who were at high risk initially or were slow early responders, receiving the additional doses. The total number of children randomised to TG or MP was 4000. Follow-up continues beyond publication in some trials. With the maximum follow-up year of 2005 in COALL-05-92, 2005 in CCG-1952 and 2008 in MRC ALL97, median follow-up of all patients alive or lost to follow-up was 8.9, 6.4 and 8.9 years, respectively. Patient numbers by initial characteristics in each trial are shown in Table 2 . Trials had similar proportions of males and children with B-lineage disease. There were somewhat more children classified as having T-cell ALL in COALL-05-92. The main difference between the trial populations was due to the inclusion of only National Cancer Institute standard-risk patients in the CCG-1952 trial, so that there were no children aged X10 years at diagnosis, compared with 21% in COALL-50-92 and 15% in MRC ALL97, and none with WBCX50 Â 10 9 /l, compared with 21% in COALL-50-92 and 18% in MRC ALL97.
There was a suggestion that the relative effect of TG might differ between trials (Figure 1a ; heterogeneity test P ¼ 0.04, I 2 ¼ 68%). Significant heterogeneity (P ¼ 0.02) was seen for isolated CNS relapse, with an increase in those allocated TG in COALL-05-92 (8 versus 2) and decrease in the other trials (33 versus 56; 17 versus 34), but this may be a chance effect due to small numbers and multiple testing. The difference between trials was not seen for any other individual outcome. CCG-1952 included only standard-risk patients, and if high-risk patients from the other trials were excluded, the heterogeneity between the three trials was no longer seen (Figure 1b ;
Overall there was a small, non-statistically significant reduction in the event rate with TG (OR ¼ 0.89, 95% CI ¼ 0.78-1.03, P ¼ 0.10). There was a reduction in the CNS relapse rate with TG (OR ¼ 0.74, 95% CI ¼ 0.58-0.95; P ¼ 0.02). Thiopurine treatments were balanced between IT therapies in CCG-1952 and between steroid types in MRC ALL97, and there was no evidence of a different effect of TG on CNS relapse between these treatment groups. The reduction in CNS relapse was offset by an increase in the rate of death in first remission in the MRC trial (OR ¼ 1.67, 95% CI ¼ 1.00-2.78, P ¼ 0.05, Table 3 ). In the latter trial, those receiving dexamethasone pulses were at increased risk of death in first remission (TG 20/354; MP 5/353; OR ¼ 3.36; 99% CI ¼ 1.02-9.43) compared with those receiving prednisolone (TG 5/396; MP 7/395; OR ¼ 0.73; 99% CI ¼ 0.16-3.17; P for heterogeneity ¼ 0.03). Exclusion of dexamethasone-treated patients further reduced the apparent difference in the National Cancer Institute standard-risk group between MRC ALL97 and the other trials and increased the estimated event rate reduction to OR ¼ 0.84, 95% There was no evidence that secondary tumours (which included several acute myeloid leukaemia, myelodysplastic syndromes, Non-Hodgkin's lymphoma, Hodgkin's disease, and malignant cancers of the bone, brain, thyroid and epithelium) were related to the use of cranial irradiation (XRT). Neither of the nine cases in CCG-1952 or nine cases in MRC ALL97 received XRT; in COALL-05-92, there were 5 cases out of 153 allocated to XRT and 3 out of 320 in the remainder (P ¼ 0.07). Six patients died without remission and these are included in the overall event rates, but not analysed separately in further analyses. The absolute reduction with TG in the proportion with CNS relapse at 5 years was 1.8%, and this resulted in a nonsignificant reduction of 2.5% in the proportion with any event at 5 years (Figure 2a) . A difference did not start to emerge until after 3 years. There was no significant difference in OS (OR ¼ 1.07, 95% CI ¼ 0.89-1.30; P ¼ 0.47), with 5-year survival being 0.9% higher with MP. In addition to the increased deaths in remission and secondary tumours, patients who relapsed had nonsignificantly poorer survival from relapse if they were in the TG group.
There was no evidence of a different effect on the overall event rate in subgroups by WBC or immunophenotype (Figure 3) . There was a possible difference between the effects in males and females (heterogeneity P ¼ 0.01). This was chiefly due to a difference in treatment effect on CNS relapses (heterogeneity P ¼ 0.0006) ( Table 3) , with a 50% reduction in the CNS relapse rate with TG for males (OR ¼ 0.52; OR ¼ 0.39-0.72; P ¼ 0.0001), but no benefit for females Table 3 Effect of thiopurine on different outcomes, overall and within age and sex subgroups (OR ¼ 1.27; 95% CI ¼ 0.85-1.89; P ¼ 0.24). There was no significant difference for non-CNS relapse or deaths in the first remission. The estimated absolute difference with TG in EFS at 5 years was 5.4% higher among males and 1.1% lower among females. Owing to better salvage of MP-treated males who relapsed than those who received TG (analysis of time from relapse to death, gave OR ¼ 1.25; 95% CI ¼ 0.94-1.66 for TG versus MP), the EFS benefit did not translate into improved OS. There was a difference between the effects on overall events in younger and older patients, with TG showing benefit for those o10 years but harmful for those aged X10 years (Figure 3 ; P ¼ 0.004). TG reduced the non-CNS relapse rate in the group aged o10 years ( Table 3 ; OR ¼ 0.81; 95% CI ¼ 0.66-0.98; P ¼ 0.03) but not in those aged X10 years (OR ¼ 1.44; 95% CI ¼ 0.89-2.33; P ¼ 0.14). There was no difference in OS by treatment for younger patients, and better survival with MP for the older ones, again because of improved survival after relapse (heterogeneity P ¼ 0.006). Differences in the effects on other outcomes were not significantly different between age groups, but the overall numbers in the older group are small, so that power to detect differences is low.
The heterogeneity of treatment effect on EFS between age groups and between males and females was confirmed by analysis of the COALL and MRC trials, excluding the CCG trial.
The effect estimates for the four groups by age and sex are shown in Table 3 and Figure 3 . There is a clear reduction in overall event rate with TG for males aged o10 years (OR ¼ 0.70; 95% CI ¼ 0.58-0.84; or OR ¼ 0.66; 95% CI ¼ 0.54-0.82, excluding dexamethasone-treated patients). The effect in this latter group was a reduction of about a quarter in the annual event rate in each of the first 5 years, resulting in an absolute benefit of 6.8% at 5 years (Figure 2b ). However, survival was not improved (OR ¼ 0.83, 95% CI ¼ 0.62-1.10).
Toxicity was a major issue in the CCG-1952 and MRC ALL97 trials, which included vincristine/steroid pulses in maintenance, but apparently not in COALL-05-92, without pulses. In MRC ALL97, 82 patients randomised to TG developed VOD:68 during maintenance and 14 in intensification, whereas the 12 who developed this in the MP arm did so during intensification courses, which contained TG. 2 One of these patients died of adenovirus infection and one patient required a liver transplant. In CCG-1952, 20% of patients randomised to TG developed VOD:182 during maintenance and 24 in intensification, whereas the three in the MP arm again developed it after receiving TG in delayed intensification. 4 No deaths occurred but one patient required a liver transplant. In both the trials, patients with these problems were switched to MP (82 cases in MRC ALL97 and 262 in CCG-1952) . Five percent of patients on TG in CCG-1952 developed disproportionate thrombocytopenia and the incidence of VOD or disproportionate thrombocytopenia was 28.5% with the higher, and 23% with the lower, starting dose. These problems were not reported in COALL-05-92, although there were more treatment interruptions in the TG group, with a 7.5-fold higher incidence of thrombocytopenia o100 Â 10 9 /l without leukocytopenia o1 Â 10 9 /l. On 10 occasions, platelet transfusions were given. The estimated increase in VOD between randomised treatments was sevenfold (OR ¼ 7.16, 95% CI ¼ 5.66-9.06).
Discussion
With the complex treatments used for childhood ALL, there are many protocol features, which can vary between trials. In these trials comparing thiopurines, there are differences in TG doses, and in the timing and type of maintenance treatment. This metaanalysis has revealed important clues about the apparent differences in results between trials, which may be at least partly due to the different patients included. By using individual patient data, it has been possible to examine treatment effects within subgroups of patients, and to look at specific outcomes separately. The different effects in males and females seen in CCG-1952 were confirmed using data from the other two trials. In addition, high-risk patients were included in these trials, allowing examination of effects in older patients not included in the CCG trial.
Possible heterogeneity of effect between males and females, and between younger and older patients suggests that TG improves EFS for males aged o10 years, the largest of the four sex/age subgroups. The event rate was reduced by 30%, resulting in an absolute difference of 6.8% at 5 years. Although the point estimates in other groups are in the favour of MP, confidence intervals are wide, and whether there is benefit or harm in these groups is unclear. On average, boys received a longer duration of treatment than girls, and this might partly explain the difference. Another reason might be differences in the way boys and girls handle the two drugs. 7, 8 Although differences were not generally statistically significant, deaths in remission and secondary tumours were more frequent with TG in all subgroups, so the treatment effect on relapse rate needs to be large enough to counteract this in order to show EFS benefit.
As salvage treatment seemed to be more successful for relapses after MP, survival benefit was not seen overall, or for any subgroup. Although TG may be more effective in preventing relapses in some types of patients, its toxicity and lack of effect on survival currently preclude its prolonged use. Ongoing pharmacogenetic studies may yet establish whether there are particular patients who could derive outcome benefit from TG.
